Kathryn McNaughton

Kathryn McNaughton has a diverse work experience spanning several pharmaceutical and biotech companies. Kathryn is currently the SVP of Portfolio & Program Management at Dunad Therapeutics. Prior to this, they founded and served as President of McNaughton Pharmaceutical Consulting, L.L.C. from 2020 to 2022.

From 2016 to 2020, Kathryn was the SVP of Portfolio and Program Management at AVROBIO, where they played a crucial role in developing their gene therapy pipeline and served as the Interim Head of Regulatory Affairs. Kathryn also contributed significantly to the growth of the company from a small, privately-held, preclinical-stage company to a publicly traded entity.

Before joining AVROBIO, from 2015 to 2016, Kathryn was again President of McNaughton Pharmaceutical Consulting, L.L.C. Prior to that, they worked at Synageva BioPharma Corp. as the Vice President of R&D Pipeline Program Management in 2014.

Kathryn's experience at Shire Pharmaceuticals was extensive and included roles such as Senior Director, Head of Program Managers from 2012 to 2014 and Program Executive, Senior Director, Program Management from 2005 to 2012. During their time at Shire, they led cross-functional teams in the development and execution of program plans for multiple orphan drug development programs. Kathryn also successfully developed VPRIV for the treatment of Gaucher disease.

Kathryn began their career at Praecis Pharmaceuticals, where they held the position of Associate Director, Program Management from 2001 to 2005. In this role, they managed cross-functional teams and established project plans for various therapeutic programs. Kathryn also served as a Senior Scientist at Praecis Pharmaceuticals from 1996 to 2001, where they contributed to the design, synthesis, and formulation of peptide-based therapeutics.

Before entering the pharmaceutical industry, Kathryn worked at Wentworth Institute of Technology as an Assistant Professor/Adjunct Faculty from 1995 to 2001.

Kathryn McNaughton obtained a Ph.D. in Chemistry from Princeton University in 1995. Prior to that, they earned a Bachelor's degree in Chemistry from Monmouth University. The start year for their education history is not provided.